Inhibrx, Inc.

NasdaqGM:INBX Stock Report

Market Cap: US$1.7b

Inhibrx Management

Management criteria checks 3/4

Inhibrx's CEO ist Mark Lappe , ernannt in Jan 2010, hat eine Amtszeit von 14.08 Jahren. Die jährliche Gesamtvergütung beträgt $1.02M , bestehend aus 63.6% Gehalt und 36.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.43% der Aktien des Unternehmens, im Wert von $117.35M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.1 Jahre bzw. 3 Jahre.

Key information

Mark Lappe

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage24.1%
CEO tenure14.3yrs
CEO ownership6.4%
Management average tenure3.3yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Oct 03

Inhibrx: Potential To Move To Registration Study With INBRX-101

Jun 10

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23
Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results

May 16
Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results

What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?

Jan 14
What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?

Inhibrx's INBRX-109 wins FDA's Fast Track status

Jan 13

Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors

Jan 05

Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues

Nov 22
Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues

Inhibrx EPS misses by $0.07

Nov 13

CEO Compensation Analysis

How has Mark Lappe's remuneration changed compared to Inhibrx's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$3mUS$675k

-US$241m

Sep 30 2023n/an/a

-US$189m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$163m

Dec 31 2022US$1mUS$650k

-US$145m

Sep 30 2022n/an/a

-US$125m

Jun 30 2022n/an/a

-US$111m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$5mUS$650k

-US$82m

Sep 30 2021n/an/a

-US$78m

Jun 30 2021n/an/a

-US$78m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$869kUS$530k

-US$76m

Sep 30 2020n/an/a

-US$75m

Jun 30 2020n/an/a

-US$74m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$864kUS$450k

-US$51m

Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD1.02M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.42M).

Entschädigung vs. Einkommen: MarkDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

CEO

Mark Lappe (55 yo)

14.3yrs

Tenure

US$2,802,021

Compensation

Mr. Mark Paul Lappe is Co-founded Inhibrx LLC in 2010. Mr. Lappe co-founded Efficacy Capital Limited in 2004 serves as its President and Managing Partner. He is the Chief Executive Officer of Inhibrx, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Mark Lappe
Founder14.3yrsUS$2.80m6.43%
$ 106.2m
Brendan Eckelman
Founder & Chief Scientific Officer14yrsUS$1.45m4.97%
$ 82.1m
Kelly Deck
Executive VP & CFO4yrsUS$1.15m0%
$ 0
Quinn Deveraux
Founderno datano datano data
Ashraf Amanullah
Executive VP & Chief Technical Operations Officerno datano datano data
Leah Pollema
VP, Corporate Secretary & General Counselno datano datano data
Charbel Helaihel
Vice President of Marketing & Commercial Planning1.2yrsno datano data
Jeffrey Jensen
Executive VP & Chief Clinical Operations Officer4.3yrsno datano data
David Matly
Executive VP and Chief Commercial & Business Development Officer2.5yrsno datano data
Carlos Bais
Executive Vice President of Translational Sciences1.9yrsno datano data
Josep Garcia
EVP & Chief Clinical Development Officerless than a yearno datano data

3.3yrs

Average Tenure

49yo

Average Age

Erfahrenes Management: INBXDas Führungsteam des Unternehmens gilt als erfahren (2.9 Jahre durchschnittliche Betriebszugehörigkeit).

Board Members

NamePositionTenureCompensationOwnership
Mark Lappe
Founder14.3yrsUS$2.80m6.43%
$ 106.2m
Stephen Howell
Member of Advisory Boardno datano datano data
Rand Mulford
Member of Advisory Boardno datano datano data
Douglas Forsyth
Independent Director6yrsUS$317.03k1.26%
$ 20.9m
Kimberly Manhard
Independent Director3.8yrsUS$298.03k0%
$ 0
John Kayyem
Independent Director6yrsUS$306.53k6.91%
$ 114.2m
Victor Nizet
Member of Advisory Boardno datano datano data
Guy Salvesen
Scientific Advisorno datano datano data
Kristiina Vuori
Independent Director2.5yrsUS$300.53k0%
$ 0
Igor Barjaktarevic
Member of INBRX-101 Scientific Advisory Board2yrsno datano data
Mark Brantly
Member of INBRX-101 Scientific Advisory Board2yrsno datano data
Kenneth Chapman
Member of INBRX-101 Scientific Advisory Board2yrsno datano data

3.2yrs

Average Tenure

59yo

Average Age

Erfahrener Vorstand: INBXDie Vorstandsmitglieder gelten als erfahren (3 Jahre durchschnittliche Amtszeit).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.